Activity of the Bcr-Abl kinase inhibitor PD180970 against clinically relevant Bcr-Abl isoforms that cause resistance to imatinib mesylate (Gleevec, STI571)

Paul La Rosée, Amie S. Corbin, Eric P. Stoffregen, Michael W. Deininger, Brian J. Druker

Research output: Contribution to journal › Article › peer-review

208 Scopus citations

Fingerprint

Dive into the research topics of 'Activity of the Bcr-Abl kinase inhibitor PD180970 against clinically relevant Bcr-Abl isoforms that cause resistance to imatinib mesylate (Gleevec, STI571)'. Together they form a unique fingerprint.

Medicine & Life Sciences